You are here

Article Text

Article menu
Download PDFPDF
Editorial commentary
Search for a prognostic biomarker in multiple sclerosis: a step in the right direction?
  1. Bruce V Taylor
  1. Correspondence to Professor Bruce V Taylor, Menzies Research Institute, University of Tasmania, Hobart, TAS 7005, Australia; bruce.taylor{at}utas.edu.au

http://dx.doi.org/10.1136/jnnp-2018-318326

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    There is a critical need for a prognostic biomarker at the time of the first symptoms of MS that predicts subsequent disability accumulation and thus can guide therapeutic interventions

    To date, no biomarker has allowed clinicians to answer the question of what the future holds for their patients with clinically isolated syndrome (CIS) with any degree of certainty. In the journal, Rathbone et al 1 provide further evidence to support the utility of the ratio of cerebrospinal fluid (CSF) immunoglobulin kappa to lambda free light chains (FLC κ:λ ratio), measured at diagnostic lumbar puncture (LP) at the time of CIS, in predicting multiple sclerosis (MS) disease progression out to 5 years post-CIS.

    Previously, MRI, clinical features, oligoclonal bands (OCBs) in CSF and serum/CSF neurofilament components have all been advanced as potential …

    View Full Text

    Footnotes

    • Contributors BVT is the sole author.

    • Funding The author is supported by A MS Research Australia Senior Clinical Research Fellowship.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles